Post-prophylaxis CMV in the letermovir era: Incidence, risk factors, and outcomes following HCT.

Jakafi (ruxolitinib) - Incyte

Prevymis (letermovir) - Merck (MSD)

cyclophosphamide - Generic mfg.

https://www.asco.org/abstracts-presentations/258892

Safah Khan; Elizabeth Darga; Kristina Nasr; Xuefei Jia; Andrew Trunk; Ronald Sobecks; Claudio Brunstein; Betty Hamilton; Zachary Yetmar

Apr 21, 2026